Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

View Our Latest Stock Analysis on CYTK Cytokinetics Stock Performance CYTK opened at $49.94 on Tuesday. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of ...

Cytokinetics Price Performance Shares of NASDAQ:CYTK opened at $49.94 on Tuesday. The company has a market cap of $5.89 billion, a P/E ratio of -9.28 and a beta of 0.82. The business has a fifty ...

A brand-new exhibition for the Oshi no Ko anime has been announced. Anime Tokyo Station will be hosting the "Let's Enjoy together!! History of Anime Series OSHI NO KO" exhibition from early ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about. Like any other informed investor ...

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks ...

This first-of-its-kind exhibition in the U.S. includes over 100 rare artifacts, providing a multifaceted view of Anne Frank as a teenager, a writer, and a symbol of resilience. The opening comes ...

NEW YORK — New York City's Center for Jewish History is hosting an Anne Frank exhibit that recreates the rooms she and her family hid in during World War II and the Holocaust. It opens Jan. 27 ...

Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart ...

Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:RPRX) deal and no mergers or acquisitions. Investors ...

Cytokinetics' aficamten shows strong potential in the $3B U.S. oHCM market, despite competition from Bristol Myers’ Camzyos. Stifel sets a $80 price target, highlighting catalysts expected over ...